[go: up one dir, main page]

ZA200700205B - Antibodies for selective apoptosis of cells - Google Patents

Antibodies for selective apoptosis of cells

Info

Publication number
ZA200700205B
ZA200700205B ZA200700205A ZA200700205A ZA200700205B ZA 200700205 B ZA200700205 B ZA 200700205B ZA 200700205 A ZA200700205 A ZA 200700205A ZA 200700205 A ZA200700205 A ZA 200700205A ZA 200700205 B ZA200700205 B ZA 200700205B
Authority
ZA
South Africa
Prior art keywords
antibodies
cells
selective apoptosis
apoptosis
selective
Prior art date
Application number
ZA200700205A
Other languages
English (en)
Inventor
Reiter Yoram
Klechevsky Eynav
Denkberg Galit
Original Assignee
Technion Res & Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Res & Dev Foundation filed Critical Technion Res & Dev Foundation
Publication of ZA200700205B publication Critical patent/ZA200700205B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ZA200700205A 2004-06-09 2007-01-08 Antibodies for selective apoptosis of cells ZA200700205B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57792004P 2004-06-09 2004-06-09

Publications (1)

Publication Number Publication Date
ZA200700205B true ZA200700205B (en) 2009-09-30

Family

ID=35503572

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200700205A ZA200700205B (en) 2004-06-09 2007-01-08 Antibodies for selective apoptosis of cells

Country Status (7)

Country Link
US (1) US20100062001A1 (xx)
EP (1) EP1763365B1 (xx)
JP (1) JP2008501781A (xx)
AU (1) AU2005251563B2 (xx)
CA (1) CA2570458C (xx)
WO (1) WO2005120166A2 (xx)
ZA (1) ZA200700205B (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
CA2750027C (en) * 2009-01-23 2020-11-10 Nsgene A/S Improved cell lines and their use in encapsulated cell biodelivery
GB0908613D0 (en) * 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
EP3613773A1 (en) * 2010-12-27 2020-02-26 Apo-T B.V. A cross linking polypeptide comprising an hexameric single chain antibody binding mhc-mage complex that induces apoptosis
US9821073B2 (en) 2010-12-27 2017-11-21 Apo-T B.V. Polypeptide that binds aberrant cells and induces apoptosis
EP3388451A1 (en) 2011-09-29 2018-10-17 Apo-T B.V. Multi specific binding molecules targeting aberrant cells
SG11201404007WA (en) 2012-01-13 2014-08-28 Apo T B V Aberrant cell-restricted immunoglobulins provided with a toxic moiety
PL2885010T3 (pl) 2012-08-16 2020-11-16 Ipierian, Inc. Metody leczenia tauopatii
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
US20160310583A1 (en) * 2013-10-03 2016-10-27 Sumitomo Dainippon Pharma Co., Ltd. Tumor antigen peptide
EP3104870A4 (en) 2014-02-14 2017-09-13 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US11066465B2 (en) 2015-12-30 2021-07-20 Kodiak Sciences Inc. Antibodies and conjugates thereof
SI3464380T1 (sl) 2016-06-02 2025-03-31 Immunocore Limited Režim doziranja za gp100-specifični tcr - anti-cd3 scfv fuzijski protein
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CA3116900A1 (en) * 2018-10-23 2020-04-30 Keros Therapeutics, Inc. Alk2 antibodies and methods of use thereof
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837477A (en) * 1993-01-15 1998-11-17 The United States Of America As Represented By The Department Of Health And Human Services T cell receptor ligands and methods of using same
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
CA2404489A1 (en) * 2000-03-27 2001-10-04 Technion Research And Development Foundation Ltd. Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
JP3810768B2 (ja) * 2001-07-13 2006-08-16 エヌティティエレクトロニクス株式会社 光導波路型マトリクス・スイッチおよびその製造方法
US6992176B2 (en) * 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1485075A4 (en) * 2002-02-20 2006-04-26 Dyax Corp MHC-PEPTIDE COMPLEX BINDING LIGANDS
EP1773383B1 (en) * 2004-05-27 2012-09-12 Jon A. Weidanz Antibodies as t cell receptor mimics, methods of production and uses thereof
US20090042285A1 (en) * 2004-05-27 2009-02-12 Weidanz Jon A Antibodies at T cell receptor mimics, methods of production and uses thereof
US20090304679A1 (en) * 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090226474A1 (en) * 2004-05-27 2009-09-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof

Also Published As

Publication number Publication date
JP2008501781A (ja) 2008-01-24
AU2005251563A1 (en) 2005-12-22
WO2005120166A2 (en) 2005-12-22
EP1763365A2 (en) 2007-03-21
CA2570458A1 (en) 2005-12-22
WO2005120166A3 (en) 2006-08-10
US20100062001A1 (en) 2010-03-11
CA2570458C (en) 2014-05-20
AU2005251563B2 (en) 2011-08-04
EP1763365B1 (en) 2016-08-10

Similar Documents

Publication Publication Date Title
ZA200700205B (en) Antibodies for selective apoptosis of cells
GB2441530B (en) Stem Cells
IL180852A0 (en) Anti-cd154 antibodies
IL181575A0 (en) Anti-ox40l antibodies
IL228033A0 (en) Antibodies
IL179672A0 (en) Anti-cd3 antibodies
IL177602A0 (en) Uses of anti-ctla-4 antibodies
IL212350A0 (en) Anti-p-selectin antibodies
IL234657A0 (en) Antibodies to p-cadherin
GB2411178A8 (en) Apparatus for culturing cells
EP1781328A4 (en) METHOD FOR DETECTING SPECIFIC ANTIBODIES TO CANCER CELLS AND ANTIBODIES SOUND
EP1910688A4 (en) MULTICHANNEL FLOW CELLS
GB0420466D0 (en) Anti-glucan antibodies
EP1869192A4 (en) FRAME MIXTURE OF ANTIBODIES
ZA200703293B (en) Cell bandage
ZA200701952B (en) Anti-OX40L antibodies
EP1820852A4 (en) HUMAN SERUM FOR CELL CULTURE
IL179956A0 (en) Antibodies for selective apoptosis of cells
HK1098947A (en) Antibodies for selective apoptosis of cells
GB0509318D0 (en) TCR-independent activation of T cells
GB0412861D0 (en) Screening of stem cells
EP1954801A4 (en) METHOD FOR ISOLATING CELLS
PL373994A1 (pl) Sposób przygotowania komórek do badania apoptozy
IL178683A0 (en) Methods of diminishing co-abuse potenitial
GB0419646D0 (en) Method of improving t cell receptors